Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Matthew S. Davids(Dana-Farber Cancer Institute), John F. Seymour(The Royal Melbourne Hospital), Stephan Stilgenbauer(Universität Ulm), Andrew W. Roberts(The Royal Melbourne Hospital), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Andrea Best(AbbVie (United States)), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), Michael Hallek(Integrated Oncology (United States)), William G. Wierda(University of Maryland, Baltimore), Jalaja Potluri(AbbVie (United States)), Su Young Kim(Yonsei University), Jeffrey A. Jones(The Ohio State University), Todd Busman(Abbott Fund), Elisa Cerri(AbbVie (United States)), Maria E. Verdugo(AbbVie (United States)), Monali Desai(AbbVie (United States))
Clinical Cancer Research
June 12, 2018
10.1158/1078-0432.ccr-17-3761
Cited by 161

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k